Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 19 November 1997
Length: 21 pages
Data source: Field research
Abstract
ImmuLogic Pharmaceutical Corporation, a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems of valuation are highlighted. The challenges posed by 'windows' for public offerings are considered.
Location:
Industries:
Size:
USD3 million revenues, 82 employees
Other setting(s):
1991
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Length: 13 pages
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 24 March 1993
Length: 2 pages
Data source: Field research
About
Abstract
ImmuLogic Pharmaceutical Corporation, a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems of valuation are highlighted. The challenges posed by 'windows' for public offerings are considered.
Settings
Location:
Industries:
Size:
USD3 million revenues, 82 employees
Other setting(s):
1991
Related
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Length: 13 pages
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 24 March 1993
Length: 2 pages
Data source: Field research